Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "CHRO"

848 News Found

Sanofi announces change in R&D leadership
People | February 14, 2023

Sanofi announces change in R&D leadership

Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim


JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
News | February 09, 2023

JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23

Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%


Need a paradigm shift for popularising ayurveda in India
News | February 07, 2023

Need a paradigm shift for popularising ayurveda in India

For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions


Budget 2023-24: Industry welcomes focus on medical research and pharma innovation
Policy | February 02, 2023

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047


Global diagnostic imaging market to reach $31.9 billion in 2023: GlobalData
Clinical Trials | January 31, 2023

Global diagnostic imaging market to reach $31.9 billion in 2023: GlobalData

Diagnostic imaging will become an increasingly vital process in healthcare


Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Drug Approval | January 21, 2023

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions


Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
News | January 19, 2023

Lupin launches Sacubitril and Valsartan combination drug for heart failure patients

Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Lonza completes expansion to Solid Form Services Facility at Bend (US) site
News | January 17, 2023

Lonza completes expansion to Solid Form Services Facility at Bend (US) site

New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement